Current and Evolving Approaches for Improving the Oral Permeability of BCS Class III or Analogous Molecules
Overview
Affiliations
The Biopharmaceutics Classification System (BCS) classifies pharmaceutical compounds based on their aqueous solubility and intestinal permeability. The BCS Class III compounds are hydrophilic molecules (high aqueous solubility) with low permeability across the biological membranes. While these compounds are pharmacologically effective, poor absorption due to low permeability becomes the rate-limiting step in achieving adequate bioavailability. Several approaches have been explored and utilized for improving the permeability profiles of these compounds. The approaches include traditional methods such as prodrugs, permeation enhancers, ion-pairing, etc., as well as relatively modern approaches such as nanoencapsulation and nanosizing. The most recent approaches include a combination/hybridization of one or more traditional approaches to improve drug permeability. While some of these approaches have been extremely successful, i.e. drug products utilizing the approach have progressed through the USFDA approval for marketing; others require further investigation to be applicable. This article discusses the commonly studied approaches for improving the permeability of BCS Class III compounds.
Sabra R, Kirby D, Chouk V, Malgorzata K, Mohammed A Pharmaceutics. 2025; 16(12.
PMID: 39771541 PMC: 11676059. DOI: 10.3390/pharmaceutics16121563.
Mokhtar H, Khodeer D, Alzahrani S, Qushawy M, Alshaman R, Elsherbiny N Front Chem. 2024; 12:1449380.
PMID: 39502139 PMC: 11537204. DOI: 10.3389/fchem.2024.1449380.
Enzymatic Synthesis of Austroeupatol Esters with Enhanced Antiprotozoal Activity.
Elso O, Bivona A, Aguilera E, Alvarez G, Sulsen V, Garcia Linares G ACS Med Chem Lett. 2024; 15(6):873-878.
PMID: 38894931 PMC: 11181509. DOI: 10.1021/acsmedchemlett.4c00070.
Ligand-Based Design of Selective Peptidomimetic uPA and TMPRSS2 Inhibitors with Arg Bioisosteres.
Muller P, Zimmer C, Frey A, Holzmann G, Weldert A, Schirmeister T Int J Mol Sci. 2024; 25(3).
PMID: 38338655 PMC: 10855164. DOI: 10.3390/ijms25031375.
Ifrah S, Dahan A, Debotton N Pharmaceutics. 2023; 15(10).
PMID: 37896277 PMC: 10610354. DOI: 10.3390/pharmaceutics15102518.